SWIFT-1 and -2 trials showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for patients with asthma with type 2 inflammation versus placebo ANCHOR-1 and -2 trials showed… Read More
The awards recognize the outstanding achievements of the world’s leading practitioners across various practice areas and sectors. TORONTO, ON – Fasken claimed the Healthcare and Life Sciences Law Firm of… Read More
Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies Long-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented… Read More
Following a national competition, AbbVie and SpinUp – the University of Toronto’s lab- based, life sciences accelerator – announce Neuropeutics Inc as recipient of first AbbVie Biotech Innovators Award Neuropeutics… Read More
VANCOUVER, BC – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, announced that topline results from the chronic cohort of the ongoing… Read More
